Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Stero Biotechs

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Stero Biotechs Report Initial Results in the Exploratory Study it Supports of CBD-Based Treatment for Covid-19 Severe Patients

              Contact the Supplier

              Lead Product(s): Cannabidiol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 25, 2021

              Details:

              Stero Biotechs reported that preliminary data from the exploratory study are encouraging. CBD has been shown to have a beneficial effect on a number of inflammatory markers that are elevated in Covid-19 patients and may have clinical merits as well.

              Kamada

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Kamada Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy

              Contact the Supplier

              Lead Product(s): COVID-19 IgG Therapy

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Israeli Health Authorities

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 19, 2020

              Details:

              The Israeli company will manufacture the product, to be supplied to the Ministry of Health, from convalescent plasma collected by the Israeli National Blood Services, a division of Magen David Adom (MADA), and additional Israeli medical institutions.

              RedHill Biopharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              US FDA Grants Orphan Drug Status to RedHill’s RHB-204 to Treat Nontuberculous Mycobacteria Disease

              Contact the Supplier

              Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

              Therapeutic Area: Infections and Infectious Diseases Product Name: RHB-204

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2020

              Details:

              Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S. potential market exclusivity to a total of 12 years.

              PharmaCompass__DigitalAd